Cat. No.: HY-N4280

7,8-Dimethoxycoumarin

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

7,8-Dimethoxycoumarin is a coumarin compound derived from Artemisia caruifolia with oral activity. 7,8-Dimethoxycoumarin inhibits mitochondrial permeability transition pore and H⁺/K⁺-ATPase, and exhibits antioxidant, anti-inflammatory, renoprotective, neuroprotective and gastroprotective effects. 7,8-Dimethoxycoumarin reduces lipid peroxidation (TBARS), increases GSH levels, inhibits myeloperoxidase (MPO) activity, and regulates the expression of inflammatory factors by inhibiting the NF‑κB and MAPK pathways. 7,8-Dimethoxycoumarin ameliorates gastric mucosal injury, alleviates renal tissue lesions and relieves neuropathic pain. 7,8-Dimethoxycoumarin can be used in studies related to acute renal failure, trigeminal neuralgia and gastritis.

For research use only. We do not sell to patients.

Purity: 99.75%
CAS No.: 2445-80-9
Formula: C₁₁H₁₀O₄
Molecular Weight:206.19

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

7,8-Dimethoxycoumarin Chemical Structure

CAS No.: 2445-80-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[2]^[3]

NF-κB

IL-6

IL-8

All Glutathione Peroxidase Isoforms :

GPX1
GPX4

All NF-κB Isoforms :

All p38 MAPK Isoforms :

All Interleukin Related Isoforms :

In Vitro

7,8-Dimethoxycoumarin (DMC) protects human keratinocyte HaCaT cells from TNF-α-induced damage through inhibition of NF-κB activation and MAPK phosphorylation^[2].
7,8-Dimethoxycoumarin stimulates melanogenesis via MAPK-mediated MITF upregulation and reduces IL-6, IL-8, and CCL2/MCP-1 expression in TNF-α-treated HaCaT cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

7,8-Dimethoxycoumarin (50-100 mg/kg; p.o.; daily; 6 consecutive days) ameliorates Cisplatin (HY-17394)-induced acute renal failure in male Sprague Dawley rats in a dose-dependent manner, with the 75 and 100 mg/kg doses producing significant renoprotective effects comparable to Cyclosporin A (HY-B0579)^[1].
7,8-Dimethoxycoumarin (100-200 mg/kg; p.o.; daily; 10 consecutive days) dose-dependently attenuates TNF-α-induced trigeminal neuralgia in rats and reversing oxidative stress and histopathological damage^[2].
7,8-Dimethoxycoumarin (50-100 mg/kg; i.p.; single dose 1 hour pre-ligation) exerts significant gastroprotective and anti-inflammatory effects in pyloric ligation-induced gastritis in rats at a dose of 100 mg/kg^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague Dawley (male, 180-250 g, cisplatin-induced)^[1]
Dosage:

50 mg/kg; 75 mg/kg; 100 mg/kg
Administration:

p.o.; daily; 6 consecutive days
Result:

Reduced serum BUN, creatinine, urinary NAG, and renal TBARS levels at 50, 75, and 100 mg/kg in a dose‑dependent manner.
Increased FrNa, creatinine clearance, renal GSH, cytochrome c oxidase activity, and ATP levels, while decreasing renal total calcium at 50, 75, and 100 mg/kg.
Attenuated cisplatin‑induced renal histopathological damage; 75 and 100 mg/kg exhibited significant renoprotection comparable to cyclosporin A.

Animal Model:

Sprague Dawley (male, 180-250 g, ischemia/reperfusion-induced)^[1]
Dosage:

50 mg/kg; 75 mg/kg; 100 mg/kg
Administration:

p.o.; daily; 6 consecutive days
Result:

Reduced serum BUN, creatinine, urinary NAG, and renal TBARS levels at 50, 75, and 100 mg/kg in a dose‑dependent manner.
Increased FrNa, creatinine clearance, renal GSH, cytochrome c oxidase activity, and ATP levels, while lowering renal total calcium at 50, 75, and 100 mg/kg.
Attenuated ischemia/reperfusion‑induced renal histopathological damage; 75 and 100 mg/kg provided significant protection comparable to cyclosporin A.

Animal Model:

Sprague Dawley (male, 180-250 g, cisplatin-induced or ischemia/reperfusion-induced)^[1]
Dosage:

25 mg/kg; 50 mg/kg; 100 mg/kg
Administration:

p.o.; single dose
Result:

Did not produce preventive or protective effects against cisplatin- or ischemia/reperfusion-induced acute renal failure at 25, 50, or 100 mg/kg.

Animal Model:

Wistar rats (male, middle-aged 12-14 months, 200-230 g, trigeminal neuralgia induced by single endoneural TNF-α injection)^[2]
Dosage:

100 mg/kg; 200 mg/kg
Administration:

p.o.; daily; 10 consecutive days
Result:

Significantly reversed TNF-α-induced increases in percentage cold chemical sensitivity and percentage mechanical sensitivity response in a dose- and time-dependent manner.
Reduced trigeminal nerve TBARS and TNF-α levels while elevating GSH levels at 100 and 200 mg/kg.
Ameliorated TNF-α-induced histopathological alterations including axonal degeneration, neuronal hypertrophy, and neurovascular injury in trigeminal nerve tissue at both tested doses.

Animal Model:

Wistar rats (either sex, fasted 24 hours prior to pyloric ligation)^[4]
Dosage:

50 mg/kg; 75 mg/kg; 100 mg/kg
Administration:

i.p.; single dose 1 hour pre-ligation
Result:

Reduced gastric volume, total acidity, ulcerative index, TBARS levels, and MPO activity at 50, 75, and 100 mg/kg in a dose-dependent manner.
Increased GSH levels at 50, 75, and 100 mg/kg in a dose-dependent manner.
Exhibited effects comparable to omeprazole and N-acetylcysteine at 100 mg/kg.

Chemical Information

CAS No. 2445-80-9
Appearance Solid
Molecular Weight 206.19
Formula C₁₁H₁₀O₄
Color White to off-white
SMILES

O=C1C=CC2=CC=C(OC)C(OC)=C2O1
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Curr Issues Mol Biol

Therapeutic Potential of 7,8-Dimethoxycoumarin in Tumor Necrosis Factor-Alpha-Induced Trigeminal Neuralgia in a Rat Model. [Abstract]

2025 Jul 4;47(7):518. PMID: 40728987

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (484.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.8499 mL

24.2495 mL

48.4990 mL

5 mM

0.9700 mL

4.8499 mL

9.6998 mL

10 mM

0.4850 mL

2.4249 mL

4.8499 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (12.12 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Muthuraman A, et al. Therapeutic potential of 7,8-dimethoxycoumarin on cisplatin- and ischemia/reperfusion injury-induced acute renal failure in rats. Naunyn Schmiedebergs Arch Pharmacol. 2012;385(7):739-748. [Content Brief]

[2]. Paramakrishnan N, et al. Therapeutic Potential of 7,8-Dimethoxycoumarin in Tumor Necrosis Factor-Alpha-Induced Trigeminal Neuralgia in a Rat Model. Curr Issues Mol Biol. 2025;47(7):518. Published 2025 Jul 4. [Content Brief]

[3]. Kang JK, et al. 4-Hydroxy-7-Methoxycoumarin Inhibits Inflammation in LPS-activated RAW264.7 Macrophages by Suppressing NF-κB and MAPK Activation. Molecules. 2020;25(19):4424. Published 2020 Sep 26. [Content Brief]

[4]. Sood S. Role of 7,8-dimethoxycoumarin in anti-secretary and anti-inflammatory action on pyloric ligation-induced gastritis in rats. J Asian Nat Prod Res. 2010;12(7):593-599.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.8499 mL	24.2495 mL	48.4990 mL	121.2474 mL
	5 mM	0.9700 mL	4.8499 mL	9.6998 mL	24.2495 mL
	10 mM	0.4850 mL	2.4249 mL	4.8499 mL	12.1247 mL
	15 mM	0.3233 mL	1.6166 mL	3.2333 mL	8.0832 mL
	20 mM	0.2425 mL	1.2125 mL	2.4249 mL	6.0624 mL
	25 mM	0.1940 mL	0.9700 mL	1.9400 mL	4.8499 mL
	30 mM	0.1617 mL	0.8083 mL	1.6166 mL	4.0416 mL
	40 mM	0.1212 mL	0.6062 mL	1.2125 mL	3.0312 mL
	50 mM	0.0970 mL	0.4850 mL	0.9700 mL	2.4249 mL
	60 mM	0.0808 mL	0.4042 mL	0.8083 mL	2.0208 mL
	80 mM	0.0606 mL	0.3031 mL	0.6062 mL	1.5156 mL
	100 mM	0.0485 mL	0.2425 mL	0.4850 mL	1.2125 mL

Keywords

7,8-Dimethoxycoumarin

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

7,8-Dimethoxycoumarin

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Antidepressant Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) 7,8-Dimethoxycoumarin

All Glutathione Peroxidase Isoforms

All NF-κB Isoforms

All p38 MAPK Isoforms

All Interleukin Related Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

7,8-Dimethoxycoumarin Related Classifications

Cat. No.: HY-N4280